摘要
探究丁苯酞联合阿伐他汀治疗急性脑梗死的临床治疗效果。选取该院2019年3月至2020年8月期间收治的92例急性脑梗死患者作为试验对象,将其随机划分为两组,管理组患者接受丁苯酞+阿托伐他汀,普通组患者仅接受阿托伐他汀治疗,对比两组患者治疗两周后的血脂水平、神经功能、运动功能、生活自理能力、炎症因子水平以及不良反应发生率等临床疗效。治疗后,管理组患者(97.83%)治疗总有效率显著高于普通组患者(86.96%)(P<0.05);管理组患者的总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)等血脂水平改善程度均优于普通组患者(P<0.05),分别达到(3.27±0.27)、(1.09±0.23)、(1.32±0.21)、(2.01±0.18)mmol/L;管理组患者的CPR(C-反应蛋白)、白细胞计数(WBC)及中性粒细胞(N)等炎性因子水平明显低于普通组患者(P<0.05),分比为(6.81±1.73)mg/L、(6.49±0.37)×10^(9)/L、56.25%±7.41%;管理组患者神经功能、运动功能以及生活自理能力的恢复程度均显著优于普通组患者(P<0.05),分别达到7.06±3.07、82.46±3.01、78.24±5.41;管理组患者(4.35%)用药不良反应略低于普通组患者(6.52%),但两者对比并无统计学意义(P>0.05)。丁苯酞联合阿托伐他汀治疗急性脑梗死临床疗效较好,用药安全性高,值得在临床中推广应用。
To explore the clinical therapeutic effect of butylphthalide combined with atorvastatin in the treatment of acute cerebral infarction,a total of 92 patients with acute cerebral infarction who were admitted to the authors'hospital from March 2019 to August 2020 were selected as the research objects,and they were randomly divided into two groups.Patients in the management group received butylphthalide+atorvastatin treatment,and patients in the general group received only atorvastatin treatment.The blood lipid levels,nerve function,motor function,self-care ability,inflammatory factor levels of the two groups of patients after two weeks of treatment,and the clinical efficacy such as the incidence of adverse reactions were compared.After treatment,the total effective rate of treatment in the management group(97.83%)was significantly higher than that in the general group(86.96%)(P<0.05).The improvement in blood lipid levels of patients in the management group such as total cholesterol(TC),triglycerides(TG),high-density lipoprotein cholesterol(HDL-C),and low-density lipoprotein cholesterol(LDL-C)were better than those in the general group(P<0.05),respectively reaching(3.27±0.27),(1.09±0.23),(1.32±0.21),(2.01±0.18)mmol/L.The levels of inflammatory factors such as CPR(C-reactive protein),white blood cell count(WBC)and neutrophil(N)in the management group were significantly lower than those in the general group(P<0.05),with a score of(6.81±1.73)mg/L,(6.49±0.37)×10^(9)/L,56.25%±7.41%.The recovery degree of nerve function,motor function and self-care ability of the management group were significantly better than that of the ordinary group(P<0.05),reaching 7.06±3.07,82.46±3.01,78.24±5.41,respectively.The adverse drug reactions of patients in the management group(4.35%)were slightly lower than those in the general group(6.52%),but the comparison between the two was not statistically significant(P>0.05).Butylphthalide combined with atorvastatin has good clinical efficacy and high drug safety in the treatment of acute
作者
钱瑾邺
陈传国
QIAN Jin-ye;CHEN Chuan-guo(The Second People's Hospital of Wuhu,Wuhu 241000,China)
出处
《药物生物技术》
CAS
2022年第4期367-371,共5页
Pharmaceutical Biotechnology
关键词
丁苯酞
阿托伐他汀
联合用药
急性脑梗死
临床
疗效
Butylphthalide
Atorvastatin
Combination medication
Acute cerebral infarction
Clinical
Efficacy
